Detection of glioblastoma response to temozolomide combined with bevacizumab based on µMRI and µPET imaging reveals [(18)F]-fluoro-l-thymidine as an early and robust predictive marker for treatment efficacy

The individualized care of glioma patients ought to benefit from imaging biomarkers as precocious predictors of therapeutic efficacy. Contrast enhanced MRI and [(18)F]-fluorodeoxyglucose (FDG)–PET are routinely used in clinical settings; their ability to forecast the therapeutic response is controve...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Corroyer-Dulmont, Aurélien, Pérès, Elodie A., Petit, Edwige, Guillamo, Jean-Sébastien, Varoqueaux, Nathalie, Roussel, Simon, Toutain, Jérôme, Divoux, Didier, MacKenzie, Eric T., Delamare, Jérôme, Ibazizène, Méziane, Lecocq, Myriam, Jacobs, Andréas H., Barré, Louisa, Bernaudin, Myriam, Valable, Samuel
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2013
Sujets:
Basic and Translational Investigations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3534417/
https://ncbi.nlm.nih.gov/pubmed/23115160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos260
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires